Here is a quote from the half yearly report. FY 2022 starts 1 July 2021. So obviously means calendar year.
"As a result, the company believes that it has sufficient capital to be able initiate a first human clinical trial of PATDX1 in 2022"
Ann: Appendix 4C - Quarterly - 31 March 2021, page-4
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.001(6.67%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $17.95K | 2.337M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 8374557 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1878035 | 6 |
View Market Depth
| Last trade - 16.10pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
0.001 ( 6.67 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.8¢ | 872435 | ||
| Last updated 15.24pm 23/05/2024 ? | |||||
| PAB (ASX) Chart |